I-CAR T-Cell Therapy e-Singapore

Bheka izibhedlela kanye nezindleko zokwelashwa kwe-CAR T-Cell eSingapore. Xhumana nathi ukuze uthole izinsiza ze-bespoke zasekupheleni.

Ukwethulwa CAR T-cell therapy in Singapore – a groundbreaking and revolutionary approach to cancer treatment. The National University Cancer Institute, Singapore (NCIS) has developed an innovative therapy that uses the immune system to fight cancer. Unlike traditional chemotherapy, CAR T Cell Therapy is customized, using the modification of a patient’s own blood cells to specifically target and eliminate cancer cells. The use of gamma-delta T cells from healthy donors improves the quality of CAR-T cells while potentially cutting treatment costs, making this therapy even more attractive. This method, developed by CytoMed Therapeutics, represents a substantial advancement in the area. The Health Sciences Authority has approved a phase 1 clinical trial that will recruit healthy blood donors for testing and patients with resistant advanced cancers for treatment. This non-personalized yet effective strategy has the potential to improve cancer care in Singapore, providing hope and new opportunities for patients and their families.

I-CAR T-Cell Therapy E-Singapore - Isimo Samanje

Ukwelashwa kwamangqamuzana e-CAR-T sekushintshe kakhulu endleleni umdlavuza olashwa ngayo, futhi iSingapore ijabule kakhulu ngalokhu kwelashwa okusha. I-Singapore yenze inqubekelaphambili enkulu ekwamukeleni i-CAR-T cell therapy ngokusebenzisa izivivinyo zokwelashwa, ubambiswano, nokwesekwa kokulawula. Lokhu kusize iziguli futhi kube nomthelela ekuthuthukisweni kokunakekelwa komdlavuza. I-Singapore isephezulu kwe-CAR-T cell therapy ngoba iyaqhubeka nokwenza ucwaningo futhi inohlelo oluhle lokunakekelwa kwezempilo. Ukwelashwa kwe-CAR T-Cell eSingapore has gained pace, giving cancer patients and their families hope.

Ngenani lezivivinyo zomtholampilo ezenzeka ku I-National University Hospital, eSingapore, I-Chimeric Agent Receptor (CAR) T-cell therapy iyakhula ngesivinini esisheshayo e-Singapore. U-Oscar Saxelby-Lee uphethwe i-acute lymphoblastic leukemia, isifo esimelana nakho konke ukwelashwa. Ingane eneminyaka emihlanu yase-United Kingdom iseSingapore ngenqubo engakaze inikezwe olunye usana emhlabeni. Umfana wandiza esuka eWorcester, eNgilandi, ezofuna uhlobo olusha lokwelapha oluhilela ukukhipha amangqamuzana amasosha omzimba egazini lesiguli futhi awafake I-Chimeric Antigen Receptor (CAR-T).

I-Singapore Health Sciences Authority (HSA) igunyaze i-Kymriah (tisagenlecleucel) njengokwelashwa kokuqala kwe-chimeric antigen receptor T-cell (CAR-T) e-Singapore ngaphansi kohlaka olusha lokulawula lweseli, izicubu, nemikhiqizo yofuzo (CTGTP). I-HSA igunyaze i-Kymriah yokwelashwa kwezingane kanye neziguli ezikhulile ezisuka eminyakeni emi-2 kuye kwengama-25 ubudala ezine-B-cell acute lymphoblastic leukemia (YONKE) ephikisayo, ekubuyeleni emuva ngemva kokufakelwa noma ekuphindeni kwesibili noma kamuva; kanye nokwelapha iziguli ezikhulile ezine-refractory (r/r) ezisakaza i-B-cell lymphoma (DLBCL) enkulu ngemva kwemigqa emibili noma ngaphezulu yokwelapha okuhlelekile.

I-receptor ibophezela kuphrotheni ethile kumaseli omdlavuza, okwenza amaseli e-CAR-T asebenze futhi abhubhise amaseli omdlavuza. Njengoba amangqamuzana egazi legazi elingisa isimiso somzimba sokuzivikela ezifweni sika-Oscar, lolu hlobo lokwelashwa kwe-CAR-T luhlukile futhi luyinkimbinkimbi, ngokusho kukaProfesa Ohlangene u-Allen Yeoh, inhloko ye-oncology yezingane e-National University Hospital (NUH). U-Oscar uzoba ngumuntu wesibili emhlabeni ukwenza le nqubo. Ingane yokuqala yelashwa ngo UNOWA eminyakeni embalwa nje emuva.

I-CAR-T cell therapy wuhlobo olusha lomuthi oseluguqule indlela abantu emhlabeni wonke abaphatha ngayo umdlavuza. I-Singapore, eyaziwa ngohlelo lwayo lwezempilo olusezingeni eliphezulu nengqalasizinda yocwaningo, yayingenye yezindawo zokuqala zokwamukela nokusebenzisa ukwelapha ngamaseli e-CAR-T. Kulesi siqeshana, sizokhuluma ngokuthi ukuphi ukwelashwa kwamaseli e-CAR-T njengamanje e-Singapore nokuthi kuzithinta kanjani iziguli ezinomdlavuza.

I-Singapore inezikhungo zezokwelapha nezikhungo zokufunda eziphakathi kwezihamba phambili emhlabeni. Lezi zindawo bezibaluleke kakhulu ekuqhubekeleni phambili kwe-CAR-T cell therapy. Izikhungo ezifana neNational Cancer Center Singapore (NCCS), National University Cancer Institute Singapore (NCIS), kanye neSingapore General Hospital (SGH) bezibambe iqhaza kakhulu ezivivinyweni zomtholampilo, izifundo zocwaningo, kanye nokunikeza i-CAR-T cell therapy ezigulini.

Ngezifundo zomtholampilo ezehlukene, ukwelashwa kwamaseli e-CAR-T kwenze inqubekelaphambili enkulu eSingapore. Izinhlobo ezahlukene zomdlavuza, njenge-leukemia, i-lymphoma, nezimila eziqinile, kube yizona okugxilwe kuzo kulezi zifundo. Imiphumela ibilokhu ikhuthaza, ikhombisa izinga eliphezulu lokuphendula kanye nezikhathi ezinde zokuxolelwa. Imiphumela emihle yenze kwaba nokwenzeka ukuthi abalawuli bagunyaze ukwelashwa kweseli le-CAR-T, okusho ukuthi manje selingasetshenziswa emisebenzini yomtholampilo.

Ukwelashwa kwamaseli e-CAR-T kuzosetshenziswa kabanzi kuphela uma kulula ukukuthola futhi kungabizi kakhulu. I-Singapore ithathe izinyathelo zokuqinisekisa ukuthi abantu bayakuthola lokhu kwelashwa okusha. Ngokuhlanganyela nezikhungo zokunakekelwa kwempilo, uMnyango Wezempilo usebenze ekwakheni imihlahlandlela kanye nezinhlelo zokubuyisela imali ukuze kube lula ngeziguli ukuthola ukwelashwa kwamaseli e-CAR-T.

I-ecosystem yokunakekelwa kwezempilo yaseSingapore igcizelela kakhulu ukubambisana phakathi kwabasebenzi bezokunakekelwa kwempilo, izifundiswa, namabhizinisi. I-Singapore ikwazile ukubamba iqhaza ocwaningweni lwamazwe ngamazwe lwe-CAR-T cell therapy ngenxa yokubambisana nezinkampani eziphezulu emhlabeni ze-biopharmaceutical. Lezi zinhlobo zezivumelwano zisheshise ucwaningo, zenza ukwelashwa kuphumelele kakhudlwana, futhi zanikeza abantu abaningi ukufinyelela ekwelashweni okuphambili.

Ukwelashwa kwamaseli e-CAR-T e-Singapore kubukeka sengathi kuzoba nekusasa eliqhakazile. Ucwaningo oluqhubekayo lugxile ekwenzeni ukwelashwa kwamaseli e-CAR-T kuphumelele futhi kuphephe, ukwehlisa imiphumela emibi yokwelashwa, kanye nokuthola izindlela zokukusebenzisela uhla olubanzi lomdlavuza. ISingapore iyisikhungo se-CAR-T cell therapy innovation ngoba izibophezele ocwaningweni nasekuthuthukisweni futhi inendawo esemthethweni esemthethweni.

Ayini Amaseli E-CAR-T Futhi Awabhubhisa Kanjani Amaseli Omdlavuza?

Amaseli e-CAR T, aziwa nangokuthi ama-Chimeric Antigen Receptor T cell, angamasosha omzimba adlala ingxenye ebalulekile ku-CAR T Cell Therapy. Lawa maseli e-T akhethekile akhiwe elabhorethri ukuze aveze isamukeli se-chimeric antigen endaweni yawo. Amaseli e-CAR T, aziwa nangokuthi ama-Chimeric Antigen Receptor T cell, angamasosha omzimba adlala ingxenye ebalulekile ku-CAR T Cell Therapy. Elabhorethri, lawa maseli e-T akhethekile aklanyelwe ukuveza isamukeli se-chimeric antigen ebusweni bawo. Le receptor ihlelelwe ukuthi ibone amaprotheni athile angaphezulu kwamaseli omdlavuza aziwa ngokuthi ama-antigen. Lapho amaseli e-CAR T ekhonjwa amasosha omzimba, abopha amaseli omdlavuza, okubangela ukusabela okuqinile kokuzivikela komzimba. Amaseli e-CAR T acushiwe ayakhula futhi ahlasele amaseli omdlavuza, awabhubhise ngempumelelo.

Yiziphi Izimo Ezingelashwa Nge-CAR T Cell Therapy eSingapore?

I-CAR T Cell Therapy iwuhlobo lokwelapha oluthuthukisiwe lwamasosha omzimba olubonise ukusebenza kahle okuphawulekayo ekwelapheni izimo ezithile, ikakhulukazi okuqondiswe ezigulini ezibhekene nezimo eziyinselele. Lokhu kwelashwa okuthuthukisiwe kufaneleka kakhulu kubantu okutholwe benezinhlobo ezinolaka eziphinde zabuyela emuva ze-Acute Lymphoblastic Leukemia (ALL), i-myeloma eminingi, kanye namacala okuphinda aqubuke ku-Non-Hodgkin Lymphoma, njenge-Diffuse Large B-cell Lymphoma (DLBCL). Lokhu kubaluleke kakhulu lapho ukwelapha kwendabuko kuhlulekile futhi okungenani izindlela ezimbili zokwelashwa ezedlule zibonakale zingasebenzi ekufinyeleleni imiphumela efiselekayo. Ngakho-ke, i-CAR T-Cell Therapy ivela njengendlela yokwelapha ethembisayo ezigulini eziphethwe i-leukemia ne-lymphoma, izinikeze ukukhanya kwethemba nesithembiso semiphumela yokwelashwa ethuthukisiwe e-Singapore.

Inqubo Elula Yokuthola I-CAR T Cell Therapy

Thumela imibiko yakho

Thumela i-imeyili ku-info@cancerfax.com nomlando wakho wezokwelapha namarekhodi, okuhlanganisa ukuhlolwa kwegazi nezikena. Lokhu kusisiza ukuthi sihlole isimo sakho futhi sikuqondise ekwelashweni komdlavuza okufanele kakhulu.

Ukuhlola Nombono

Sizokusiza ukuthi uthole i-visa yezokwelapha futhi ulungiselele izinhlelo zakho zokuhamba ukuze uqinisekise uhambo olushelelayo lokululama kulesi sifo.

I-visa yezokwelapha kanye nokuhamba

Abasebenzi bethu abanokuhlangenwe nakho bazohlaziya imibiko yakho futhi bakunikeze ukuhlolwa okuphelele nezeluleko zochwepheshe ezitusa izibhedlela nochwepheshe abafanelekile.

Ukwelashwa nokulandelela

Ithimba lethu elizinikele lizoqhubeka nokukuphelezela kuyo yonke inqubo yokwelashwa uma usufike esibhedlela osithandayo.

Kungani ukhethe i-Singapore ukuthola ukwelashwa kwe-CAR T-Cell?

Ingqalasizinda Yezokwelapha Ethuthukisiwe

I-Singapore yaziwa ngobuchwepheshe bayo obusezingeni eliphezulu kanye nezikhungo zezokwelapha ezisezingeni lomhlaba. Uhulumeni ubeke imali eningi ekunakekelweni kwezempilo futhi unohlelo oluqinile futhi olufinyelela emazingeni omhlaba. Ngo-2010, i-WHO yabeka uhlelo lwezempilo lwaseSingapore endaweni yesithupha kweziyi-100 ezihamba phambili emhlabeni. Njengamanje, izibhedlela ezingama-22 nezinye izikhungo zezokwelapha eSingapore zigunyazwe yi-Joint Commission International (JCI).

Ochwepheshe Bezokwelapha Abanekhono Eliphezulu

I-Singapore inodokotela abaningi abanekhono nabanolwazi olunzulu, okuhlanganisa nodokotela begazi kanye nodokotela begazi abasebenza ngokukhethekile ekwelashweni kwamaseli e-CAR-T. Laba chwepheshe baye baqeqeshwa e-U.S. nakwamanye amazwe, futhi abaningi babo baye basebenza noma bafunda ezikhungweni zezokwelapha ezaziwayo phesheya.

Imithetho Eqinile Nokulawulwa Kwekhwalithi

Ibhizinisi lokunakekelwa kwezempilo eSingapore lilawulwa yimithetho eqinile kanye nokuhlolwa kwekhwalithi. Izikhulu zezempilo ezweni, njenge-Health Sciences Authority (HSA), ziqinisekisa ukuthi ukwelapha, njengokwelashwa kweseli ye-CAR-T, kuhlangabezana nezindinganiso eziqinile zokuphepha nokusebenza. Lokhu kunikeza iziguli zakwamanye amazwe ezifuna ukuthola ukwelashwa eSingapore ukuthula kwengqondo.

Imvelo Ehlukene Yamasiko NesiNgisi

ISingapore iyidolobha elinamasiko nabantu abaningi abahlukene, futhi isiNgisi singolunye lwezilimi zalo ezaziwayo. Lokhu kwenza kube indawo enhle ezigulini zakwamanye amazwe ukuya kuzo ngoba ukuxhumana kulula futhi kuyashesha. Iziguli ezisuka kwamanye amazwe zingakhuluma nodokotela bazo kalula, zifunde izindlela zazo zokwelashwa, futhi zinakekele izinkinga zazo zezokwelapha.

Inqubo Yokwelapha Ye-CAR-T Cell Therapy

Inqubo ye-CAR-T Cell Therapy Treatment iqukethe lezi zigaba ezinkulu ezilandelayo:

Ukubonisana kwasekuqaleni:

Isiguli esiphethwe umdlavuza kufanele sibonane nodokotela oyi-oncologist ukuze axoxe ngokufaneleka kwaso ukuthola i-CAR-T Cell Therapy.

Udokotela uzokwenza umlando wezempilo ophelele kanye nokuhlolwa kokuxilonga kwesiguli.

Ngemuva kokuhlolwa, isiguli sizokwaziswa ngezingozi zokwelashwa, izinzuzo, kanye nalokho okulindelwe.

Ukuqoqwa Kweseli Nokulungiswa:

Ama-T cell aqoqwa esigulini kusetshenziswa indlela efana nokunikela ngegazi ebizwa ngokuthi i-apheresis.

Lawa maseli T akhiwe ngofuzo elebhu ukuze aveze i-chimeric antigen receptor (CAR).

Amaseli ashintshiwe ayakhuliswa futhi aphindaphindwe ukuze kukhiqizwe inani elanele lamaseli e-CAR T.

Indlela Yokumnika:

Ukukhiqiza indawo efanele ukusebenza kwamaseli e-CAR T, isiguli sidlula enqubweni yokulungisa isimo, ngokuvamile ehilela ukwelapha ngamakhemikhali omthamo omncane.

Amaseli e-CAR T ashintshiwe abe esebuyiselwa egazini lesiguli.

Amaseli e-CAR T ajikeleza emzimbeni, akhombe futhi anamathisele kumaseli omdlavuza aveza ama-antigen athile.

Ukuqapha kanye Nokulandelela:

Ngemuva kwayo yonke inqubo yokumnika, isiguli sizobhekwa ngokucophelela ngemiphumela emibi engase ibe khona kanye nempendulo yokwelapha.

Ukuqokwa kokulandelela kuhlelwa njalo ukuze kuhlolwe ukusebenza kahle kokwelashwa nokusingatha noma yiziphi izinkinga ezikhulayo.

Ukuqapha isikhathi eside kuqinisekisa imiphumela enenzuzo futhi kubhekana nanoma yiziphi izinkinga ezingase zibe khona ezigulini ezinomdlavuza.

Zithini Izindleko Zokwelashwa Kweseli I-CAR T ESingapore?

Kymriah CAR T-cell therapy, which the Singapore Medical Council has approved for the treatment of diffuse large B-cell lymphoma and B-cell acute lymphoblastic leukemia, can cost up to $ 475,000 USD i.e around $ 700,000 SGD.

Ochwepheshe Be-CAR T-Cell Therapy E-Singapore

Thatha umbono wesibili wochwepheshe mayelana nokumnika kwe-CAR T-Cell therapy ovela kochwepheshe abahamba phambili e-Singapore.

Iphrofayela: Umqondisi Wezokwelapha kanye nomeluleki omkhulu esikhungweni somdlavuza iParkway esigabeni se-oncology. UDkt Ang uyilungu lomkhandlu we-Singapore Cancer Society. Ubuye waba nguMongameli owedlule weSingapore Society of Oncology.

Iphrofayela: UDkt Colin uthole iziqu zakhe zobudokotela e-National University of Ireland ngo-2002 wabe esephothula i-Internal Medicine yokuhlala kanye nokuqeqeshwa okukhethekile kwe-Hematology e-Singapore General Hospital.

Izibhedlela Eziphezulu Ze-CAR T-Cell Therapy E-Singapore

Parkway Cancer Centre

Okusha immunotherapy indlela eyaziwa ngokuthi i-CAR T-cell therapy ibonise isithembiso esingavamile ekwelapheni izifo ezihlukahlukene ezibulalayo. I-Beijing, isibhedlela somdlavuza sase-China sase-Peking University sesiphenduke umholi womhlaba wonke ekuthuthukisweni kokwelashwa kwe-CAR T-cell. Ngosizo lwethimba labo lezinhlaka eziningi, elihlanganisa ongoti be-oncologists, odokotela bamasosha omzimba, nezazi zofuzo, ukwelashwa komdlavuza okuqondene nomuntu kuthuthuke kakhulu. Isibhedlela Somdlavuza sase-Peking University sithole imiphumela evelele ezigulini ezine-hematological malignancies ngokushintsha ama-T cell eziguli ukuze aveze ama-chimeric antigen receptors (CARs). Lokhu kwelashwa kunikeza iziguli ezinomdlavuza ithemba elisha futhi kukhuphule amazinga okusinda.

Iwebhusayithi

I-National University Cancer Institute, eSingapore

I-National University Cancer Institute (NCIS) eSingapore iyindawo eyaziwayo esebenzela ukugwema, ukuxilonga, nokwelapha umdlavuza. Njengengxenye yoHlelo Lwezempilo Lwenyuvesi Kazwelonke, i-NCIS inikeza abantu abanomdlavuza ukunakekelwa okugcwele nokuhlelekile. Lesi sikhungo sihlanganisa ubungcweti bomtholampilo, ucwaningo olusezingeni eliphezulu, kanye nemfundo ukuze siqhamuke nezinhlelo zokwelashwa eziqondene nawe ezisekelwe ebufakazini besayensi. I-NCIS inamathuluzi esimanjemanje, njengobuchwepheshe bezithombe obusezingeni eliphezulu kanye nemishini ye ukwelashwa kwemisebe. Baphinde banikeze izindleko ezingabizi zokwelashwa kwe-proton eSingapore.

Iwebhusayithi

Yiziphi Izinzuzo Ze-CAR-T Cell Therapy?

Inzuzo eyinhloko ukuthi ukwelashwa kwe-CAR T-cell kudinga kuphela ukumnika okukodwa futhi ngokuvamile kudinga kuphela amasonto amabili okunakekelwa kwesiguli. Iziguli ezine-non-Hodgkin lymphoma kanye ne-leukemia yezingane ezisanda kutholwa, ngakolunye uhlangothi, ngokuvamile zidinga imiphumela emibi yokwelashwa ngamakhemikhali okungenani izinyanga eziyisithupha noma ngaphezulu.

Izinzuzo zokwelashwa kwe-CAR T-cell, okuwumuthi ophilayo, kungaqhubeka iminyaka eminingi. Uma futhi kwenzeka ukuphindeka, amaseli azokwazi ukuhlonza futhi aqondise amaseli omdlavuza ngoba angaphila emzimbeni isikhathi eside.

Nakuba ulwazi lusathuthuka, u-42% weziguli ze-lymphoma zabantu abadala ezathola ukwelashwa kwe-CD19 CAR T-cell zazisenoshwele ngemva kwezinyanga eziyi-15. Futhi ngemva kwezinyanga eziyisithupha, izingxenye ezimbili kwezintathu zeziguli ezine-acute lymphoblastic leukemia zazisaxole. Ngeshwa, lezi ziguli zinezimila ezinolaka kakhulu ezingazange zilashwe ngempumelelo kusetshenziswa izindinganiso zendabuko zokunakekela.

Hlobo Luni Lweziguli Ezingaba Abamukeli Abakahle Bokwelashwa Kweseli Le-CAR-T?

Iziguli ezineminyaka ephakathi kwemi-3 kuya kwengu-70 zizame ukwelashwa nge-CAR T-Cell ngezinhlobo ezahlukene zomdlavuza wegazi futhi kusebenza kahle kakhulu. Izikhungo eziningi ziye zafuna amanani empumelelo angaphezu kuka-80%. Umuntu ongcono kakhulu wokwelashwa kwe-CAR T-cell ngalesi sikhathi yingane ene-acute lymphoblastic leukemia noma umuntu omdala one-B-cell lymphoma enamandla osevele enemigqa emibili yokwelapha okungasebenzi.

Ngaphambi kokuphela kuka-2017, lalingekho izinga elamukelekayo lokunakekela ezigulini esezidlule emigqeni emibili yokwelashwa ngaphandle kokuthola ukuxolelwa. Okuwukuphela kwendlela yokwelapha egunyazwe i-FDA kuze kube manje osekufakazele ukuthi kunenzuzo enkulu kulezi ziguli ukwelapha nge-CAR T-cell.

Isebenza Kangakanani I-CAR-T Cell Therapy?

Ukwelashwa kwe-CAR T-cell kube yimpumelelo kakhulu ekwelapheni ezinye izinhlobo zomdlavuza wegazi, njenge-acute lymphoblastic leukemia (ALL) kanye ne-non-Hodgkin lymphoma. Ezivivinyweni zemitholampilo, amazinga okuphendula abe mahle kakhulu, futhi iziguli eziningi ziye zangena ekwelashweni okuphelele. Kwezinye izimo, abantu ababezame yonke eminye imithi baba nokukhululwa okuhlala isikhathi eside noma ngisho nokwelashwa okungenzeka.

Enye yezinto ezinhle kakhulu ngokwelashwa kwe-CAR T-cell ukuthi iqondise kumaseli afanele. Ama-receptor e-CAR angezwe kuma-T cell angathola amamaki athile kumaseli omdlavuza. Lokhu kwenza kube nokwenzeka ukunikeza ukwelashwa okuhlosiwe. Le ndlela ehlosiwe ilimaza amaseli anempilo kancane ngangokunokwenzeka futhi yehlisa ubungozi bemiphumela engemihle eza nokwelashwa kwendabuko okufana nokwelapha ngamakhemikhali.

Kodwa kubalulekile ukukhumbula ukuthi ukwelashwa kwe-CAR T-cell kuseyindawo entsha esashintsha. Abacwaningi nodokotela basebenza kanzima ukuxazulula izinkinga ezifana nezindleko eziphezulu, amathuba okuba nemiphumela emibi kakhulu, kanye neqiniso lokuthi kusebenza kuphela ezinhlotsheni ezithile zomdlavuza.

Ekugcineni, ukwelashwa kwe-CAR T-cell kubonise ukuthi kuyindlela ephumelela kakhulu yokwelapha ezinye izinhlobo zomdlavuza wegazi. Noma kuyindlela ethembisayo futhi enamandla, izifundo eziningi nezivivinyo zomtholampilo ziyadingeka ukuze kuthuthukiswe futhi kutholwe izindlela ezintsha zokuyisebenzisa. Ukwelashwa kwe-CAR T-cell kungashintsha indlela umdlavuza welashwa ngayo futhi kwenze izinto zibe ngcono kubantu emhlabeni wonke uma uqhubeka nokuba ngcono.

Ngubani Ofanelekela I-CAR T Cell Therapy eSingapore?

E-Singapore, ukufaneleka kwe-CAR T Cell Therapy kuyakhethwa futhi kwenzelwa ukusebenza kahle okuphezulu.

Iziguli ezifanele izingane kanye nabantu abadala abasebasha (abaneminyaka engu-3-25 ubudala) abane-B-cell Acute Lymphoblastic Leukemia (YONKE) engazweli futhi abaphinde babuyela emuva ngemva kokufakelwa.

I-CAR T Cell Therapy iyatholakala nakubantu abadala abane-Diffuse Large B-cell Lymphoma (DLBCL) abangazange baphendule okungenani ukwelashwa okujwayelekile okubili.

Kodwa-ke, amaqembu athile eziguli angase angahlangabezani nenqubo yokufaneleka, okuhlanganisa lawo anomfutho wegazi ophezulu we-intracranial noma ukuquleka, ukwehluleka ukuphefumula, ukusabalalisa i-intravascular coagulation, i-hematosepsis, noma ukutheleleka okusebenzayo okungalawuleki nesifo sikashukela. Ukukhethwa ngokucophelela kweziguli ezifanele kuqinisekisa ukuthi i-CAR T Cell Therapy inikezwa abantu abazozuza kakhulu, okwandisa amathuba okuba nemiphumela emihle kakhulu yokwelashwa.

Ukwelashwa Kwe-CAR T-Cell Kugunyazwe Yi-USFDA

UKYMRIAH

I-B-cell precursor acute lymphoblastic leukemia, ebuyele emuva noma i-refractory isakaza i-B-cell lymphoma enkulu

Izinga lokuphendula eliphelele (CR): >90%

Ithagethi: CD19

Price: $ 475,000

Isikhathi sokugunyaza: Agasti 30, 2017

YESCARTA

I-B-cell lymphoma enkulu ebuyele emuva noma ephikisayo, ebuyele emuva noma ephikisayo ye-follicular cell lymphoma.

Izinga lokuphendula eliphelele le-Non-Hodgkin's lymphoma (CR): 51%

Ithagethi: CD19

Price: $ 373,000

Isikhathi sokugunyazwa: 2017 Okthoba 18

TECARTUS

I-B-cell lymphoma ebuyiselwe emuva noma ephikisayo

I-Mantle cell lymphoma Izinga lokuphendula eliphelele (CR): 67%

Ithagethi: CD19

Price: $ 373,000

Isikhathi esivunyelwe: Okthoba 18, 2017

BREYANZI

I-B-cell lymphoma ebuyiselwe emuva noma ephikisayo

Izinga lokuphendula eliphelele (CR): 54%

Ithagethi: CD19

Price: $ 410,300

Isikhathi esivunyelwe: Okthoba 18, 2017

I-ABECMA

I-Myeloma Ephindaphindekayo noma Ephikisayo

Izinga lokuphendula eliphelele: 28%

Ithagethi: CD19

Price: $ 419,500

Kuvunyelwe: Okthoba 18, 2017

Yimiphi imiphumela emibi ye-CAR-T Cell Therapy?

Ngezansi eminye yemiphumela emibi yokwelashwa kwe-CAR T-Cell.

I-Cytokine release syndrome (CRS): Umthelela oseceleni ovame kakhulu futhi okungenzeka ubaluleke kakhulu wokwelashwa kwe-CAR T-cell i-cytokine release syndrome (CRS). Izimpawu ezinjengomkhuhlane, okuhlanganisa imfiva, ukukhathala, ikhanda elibuhlungu, nobuhlungu bemisipha, zibangelwa ukukhiqizwa kwama-T cell ashintshiwe ama-cytokines. Ezimweni ezimbi kakhulu, i-CRS ingase ibangele izinga lokushisa eliphezulu, i-hypotension, ukwehluleka kwezitho, ngisho nemiphumela engase ibulale.
Ubuthi Bezinzwa: Ezinye iziguli zingase zibe nemiphumela engemihle yemizwa, engase ihluke kakhulu kusukela kuzimpawu ezingathí sina njengokudideka okuncane kanye nokudideka kuye kwezibucayi kakhulu njengokuquleka, ukudangala, kanye ne-encephalopathy. Ngemuva kokujova i-CAR T-cell, ubuthi bezinzwa buvame ukwenzeka phakathi nesonto lokuqala.
I-Cytopenias: Ukwelashwa kwe-CAR T-cell kungabangela ukubala kwamangqamuzana egazi aphansi, njenge-anemia (isibalo esiphansi samangqamuzana egazi abomvu), i-neutropenia (isibalo esiphansi samangqamuzana egazi amhlophe), kanye mthombosia (isibalo seplatelet esiphansi). Amagciwane, ukopha, nokukhathala kuphakathi kwezingozi ezingabhebhethekiswa yilezi cytopenias.
Amagciwane: Ukucindezela kwe-CAR T-cell therapy kwamangqamuzana omzimba anempilo kwandisa ingozi yokutheleleka ngamagciwane, igciwane, kanye nesikhunta. Ukuze kuvinjwe izifo, iziguli kungase kudingeke ukuthi zibhekwe ngeso elibukhali futhi zinikezwe imithi yokuzivikela.
I-Tumor Lysis Syndrome (TLS): Ngemva kokwelashwa kwe-CAR T-cell, kwezinye izimo kungenzeka ukuthi amanani amakhulu wokuqukethwe kwamangqamuzana akhishelwe emithanjeni yegazi ngenxa yokubulawa ngokushesha kwamaseli esimila. Lokhu kungase kubangele ukuphazamiseka kwezinqubo ze-metabolic, okufana namazinga e-potassium eningi, i-uric acid, ne-phosphate, okungase kulimaze izinso futhi kubangele nezinye izinkinga.
I-Hypogammaglobulinemia: Ukwelashwa kwe-CAR T-cell kunamandla okunciphisa ukwakheka kwe-antibody, okungase kubangele i-hypogammaglobulinemia. Lokhu kungase kwenze izifo eziphindelelayo zibe nokwenzeka kakhulu futhi kubize ukuqhubeka kwemithi yokubuyisela amasosha omzimba.
Ubuthi Bomzimba: I-CAR T-cell therapy inamandla okulimaza izitho eziningi, okuhlanganisa inhliziyo, amaphaphu, isibindi, nezinso. Lokhu kungase kuholele ekuhlolweni kokusebenza okungavamile kwezinso, izinkinga zokuphefumula, izinkinga zenhliziyo, nokuhlolwa kokusebenza okungavamile kwesibindi.
I-Hemophagocytic lymphohistiocytosis (HLH): Isifo esingandile kodwa esibulalayo esibizwa ngokuthi i-hemophagocytic lymphohistiocytosis (HLH) singakhula ngenxa yokwelashwa kwe-CAR T-cell. Kuhilela ukusebenza ngokweqile kwamangqamuzana omzimba omzimba, okubangela ukulimala okukhulu kwezitho nokuvuvukala.
I-Hypotension kanye nokugcinwa koketshezi: Njengomphumela wama-cytokines akhishwa amaseli e-CAR T, ezinye iziguli zingase zibe nomfutho wegazi ophansi (hypotension) nokugcinwa koketshezi. Ukubhekana nalezi zimpawu, kungase kudingeke izinyathelo ezisekelayo ezihlanganisa uketshezi olufakwa emthanjeni nezidakamizwa.
Izifo Zesibili: Imibiko yezifo zesibili ezibulalayo ezivela ngemva kokwelashwa kwe-CAR T-cell ikhona, kungakhathaliseki ukuthi inqabile. Njengamanje ucwaningo luyenziwa mayelana namathuba ezifo zesibili kanye nezingozi zesikhathi eside.

Kubalulekile ukukhumbula ukuthi akusona sonke isiguli esizoba nale miphumela engemihle nokuthi izinga lomuntu ngamunye lokuzwela lizohluka. Ukuze kuncishiswe futhi kuncishiswe le miphumela emibi engaba khona, ithimba lezokwelapha lihlolisisa iziguli ngaphambi, phakathi, nangemuva kokwelashwa kwe-CAR T-cell.

Ubude besikhathi

Bheka ngezansi kwengqikithi yesikhathi esidingekayo ukuze kuqedelwe inqubo yokwelapha ye-CAR T-Cell. Kodwa-ke, isikhathi esinqunyiwe sincike kakhulu ebangeni lelebhu esuka esibhedlela elungise ama-CAR.

Ukuhlolwa nokuhlolwa: isonto elilodwa
Ukwelashwa kwangaphambili & Ukuqoqwa kwe-T-Cell: isonto elilodwa
Ukulungiswa kwe-T-Cell nokubuya: amasonto amabili kuya kwamathathu
Ukuhlaziywa kwe-1st Ukusebenza kahle: amaviki amathathu
Ukuhlaziywa kwe-2nd Ukusebenza kahle: amaviki amathathu.

Isikhathi esiphelele: 10-12 Amaviki

Singakusiza Kanjani Ukuthola Ukwelashwa Okungcono Kakhulu Kwe-CAR T ESingapore?

Ukuthola ukwelashwa okufanele kwe-CAR-T e-Singapore kungase kube nzima, kodwa thina kwaCancer Fax sikhona ukuze sikusize ngazo zonke izinyathelo zakho. Siyaqonda ukuthi impilo yakho ibaluleke kangakanani, futhi ukudela ikhwalithi yokunakekelwa akuyona inketho. Sakhe ukuxhumana nodokotela abanekhono eliphezulu futhi sabambisana nezibhedlela ezimbalwa ezaziwayo ukuze sikunikeze ukukhetha kwamaphoyinti entengo ahambisana nezidingo zakho, njengomngane othembekile. Umgomo wethu uwukukusiza ukuthi ufinyelele ku-CAR T Cell Therapy engcono kakhulu ngaphandle kokufaka ubunzima emalini yakho. Indlela yethu ephelele yokunakekelwa komdlavuza isivele yeseka iziguli ezivela emazweni ahlukahlukene. Sithembe ukuthi sizokuqondisa futhi siqinisekise ukuthi uthola ukwelashwa okungcono kakhulu ukuze ulwe nomdlavuza futhi ululame maduze.

I-CAR T-Cell Therapy e-Singapore

Bheka izibhedlela kanye nezindleko zokwelashwa kwe-CAR T-Cell eSingapore. Xhumana nathi ukuze uthole izinsiza ze-bespoke zasekupheleni.